These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20104126)

  • 1. Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors.
    Guaraldi G; Stentarelli C; Orlando G; Zona S; Carli F; Ballestri S; Lonardo A; Squillace N; Loria P
    J Acquir Immune Defic Syndr; 2010 Feb; 53(2):278; author reply 278-81. PubMed ID: 20104126
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperlactataemia and hepatic steatosis: mitochondrial toxicity of nucleoside reverse transcriptase inhibitors.
    Pao D; Watson C; Peters B; Lucas SB; Miller RF
    Sex Transm Infect; 2001 Oct; 77(5):381-4. PubMed ID: 11588287
    [No Abstract]   [Full Text] [Related]  

  • 3. [Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment].
    Haas S; Rockstroh JK; Spengler U; Fischer HP
    Pathologe; 2004 Sep; 25(5):406-11. PubMed ID: 15179522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside reverse-transcriptase inhibitor use, cirrhosis, and end-stage liver disease in HIV-infected patients.
    Remtulla RA; Decker CF
    Clin Infect Dis; 2008 Nov; 47(9):1233-4; author reply 1234. PubMed ID: 18831698
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis.
    Akhtar MA; Mathieson K; Arey B; Post J; Prevette R; Hillier A; Patel P; Ram LJ; Van Thiel DH; Nadir A
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1194-204. PubMed ID: 18989143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riboflavin treatment of antiretroviral induced lactic acidosis and hepatic steatosis.
    Posteraro AF; Mauriello M; Winter SM
    Conn Med; 2001 Jul; 65(7):387-90. PubMed ID: 11508132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications?
    Ingiliz P; Benhamou Y
    J HIV Ther; 2009 Mar; 14(1):3-7. PubMed ID: 19731558
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy.
    Duong Van Huyen JP; Landau A; Piketty C; Bélair MF; Batisse D; Gonzalez-Canali G; Weiss L; Jian R; Kazatchkine MD; Bruneval P
    Am J Clin Pathol; 2003 Apr; 119(4):546-55. PubMed ID: 12710127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fatty liver and increased serum lactate in a woman with HIV].
    Lichterfeld M; Fischer HP; Spengler U; Rockstroh JK
    Dtsch Med Wochenschr; 2003 Jan; 128(3):81-4. PubMed ID: 12529837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment.
    Cornejo-Juárez P; Sierra-Madero J; Volkow-Fernández P
    Arch Med Res; 2003; 34(1):64-9. PubMed ID: 12604378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management.
    Bongiovanni M; Tordato F
    Curr HIV Res; 2007 Sep; 5(5):490-8. PubMed ID: 17896969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-nucleoside reverse transcriptase inhibitors. First line therapy].
    MMW Fortschr Med; 2000; 142(3 Suppl):34-5. PubMed ID: 10893964
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
    Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
    HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
    Rubio A; Monpoux F; Huguon E; Truchi R; Triolo V; Rosenthal-Allieri MA; Deville A; Rosenthal E; Boutté P; Tran A
    J Pediatr Gastroenterol Nutr; 2009 Nov; 49(5):599-606. PubMed ID: 19668009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors.
    Boffito M; Marietti G; Audagnotto S; Raiter R; Di Perri G
    Clin Infect Dis; 2002 Feb; 34(4):558-9. PubMed ID: 11797190
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-HIV drug update.
    Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic steatosis and ddI, d4T use.
    Bernard EJ
    IAPAC Mon; 2006 Jul; 12(7):240-1. PubMed ID: 17096496
    [No Abstract]   [Full Text] [Related]  

  • 20. Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
    Morlese JF; Qazi NA; Gazzard BG; Nelson MR
    AIDS; 2002 Sep; 16(13):1840-1. PubMed ID: 12218402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.